SAO · RDOR3.SA
Rede D'Or São Luiz S.A.
R$31.48-R$0.87 (-2.69%)
Rede D'Or São Luiz S.A.’s quoted price sits in the lower half of its reported 52-week range, 34.97% below the high.
Loading market information…
SAO · HYPE3.SA · BRL
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:18 PM UTC. Cached market data; not a live quote.
One-year closing-price history · BRL. Historical prices are not a forecast.
Hypera S.A.’s quoted price sits in the lower half of its reported 52-week range, 29.47% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Hypera S.A.’s forward annual dividend is R$1.05 per share, paid quarterly. The forward yield is 4.97% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Hypera S.A.’s next earnings report is currently expected on Feb 19, 2027, with estimated earnings per share of R$0.73. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Hypera S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Based in São Paulo, Brazil, Hypera S.A. is a prominent pharmaceutical enterprise. The company's comprehensive product line encompasses a wide array of prescription medications, featuring established brands such as Adacne, Celestamine, Cizax, Diprosone, and Emprol XR, among many others. Beyond prescription drugs, Hypera offers specialized dermo-cosmetics through its Mantecorp Skincare brand. Its consumer health division markets popular remedies like Apracur, Benegrip, Engov, and Estomazil. Additionally, Hypera provides nutritional and vitamin supplements, including well-known names such as Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal. The company also maintains a significant presence in the generic and similar medicines market, offering products under the Neo Química brand and common formulations like Ibuprofen, Paracetamol, and Omeprazole. The organization officially became Hypera S.A. in February 2018, having previously operated as Hypermarcas S.A.
Latest available per-share figures in BRL. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:33 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2025 |
|---|
| Aug 6, 2025 |
| R$0.67+5.02% vs estimate |
| R$2.15B-0.09% vs estimate |
| Q1 2025 | Apr 24, 2025 | -R$0.22+4.35% vs estimate | R$1.08B-52.99% vs estimate |
|---|
| Q4 2024 | Mar 20, 2025 | R$0.13+1,200.0% vs estimate | R$1.51B+1.97% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
R$31.48-R$0.87 (-2.69%)
Rede D'Or São Luiz S.A.’s quoted price sits in the lower half of its reported 52-week range, 34.97% below the high.
R$14.25-R$0.52 (-3.52%)
Bradsaude S.A.’s quoted price sits in the upper half of its reported 52-week range, 14.06% below the high.
R$15.04-R$0.46 (-2.97%)
Raia Drogasil S.A.’s quoted price sits in the lower half of its reported 52-week range, 45.15% below the high.
R$20.47-R$0.27 (-1.3%)
Fleury S.A.’s quoted price sits in the lower half of its reported 52-week range, 28.55% below the high.
R$3.02+R$0.07 (+2.37%)
Diagnósticos da América S.A.’s quoted price sits in the lower half of its reported 52-week range, 47.84% below the high.
R$9.10-R$0.25 (-2.67%)
Blau Farmacêutica S.A.’s quoted price sits in the lower half of its reported 52-week range, 37.24% below the high.
R$4.12-R$0.11 (-2.6%)
Hapvida Participações e Investimentos S.A.’s quoted price sits in the lower half of its reported 52-week range, 87.43% below the high.
R$5.34-R$0.01 (-0.19%)
Biomm S.A.’s quoted price sits in the lower half of its reported 52-week range, 45.23% below the high.
